Galeterone shows activity in a variant form of castration-resistant prostate cancer

Galeterone shows activity in an alternative form of castration-resistant prostate cancer Today – 16:51 GMT Results from a trial of the anti-cancer medicine galeterone shows that it succeeds in lowering prostate-specific antigen (PSA) levels in guys with a type of prostate cancer that is immune to therapy containing hormone therapy [...] Read More